Bryan White
@bryan_p_white
Followers
718
Following
10K
Media
371
Statuses
2K
Great to see our ex-fellow @JosephSassineMD from U of Oklahoma presenting data on liver TX and letermovir prophylaxis! @ChemalyRoy
#CMV
1
2
26
Also out now in @AmJMedSci our review of infectious complications of CAR T and BsAb, with @OUCollegeofMed ID fellow Bradley Dye, @danieljgromer @Maryam7835Bibi @Emily_Siegrist
https://t.co/A7FoCDqBXN
amjmedsci.org
Chimeric antigen receptor (CAR) T cell therapy has shifted the therapeutic landscape of hematological malignancies in the last decade, and bispecific antibodies (BsAb) are an emerging treatment for...
0
3
13
Come work as an ID pharmacist at @UCSFHospitals! See the craziest cases, collaborate with the coolest pharmacists and physicians, teach trainees from pharmacy students to ID fellows! https://t.co/y8Lq0QSxnk
0
1
6
Finally published 🆕🔥DOTS RCT Among participants with complicated S aureus bacteremia who achieved blood culture clearance, dalbavancin was not superior to standard therapy for achieving a more desirable outcome at day 70 @DrToddLee @BradSpellberg
https://t.co/QOslh6RLX1
3
50
162
#IDTwitter OPEN ACCESS @ASHE_Journal Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy https://t.co/kUiCUR0c2N
0
3
5
(IQR 9-16) providing some support for the IDSA guideline recommendation for weekly lab monitoring on daptomycin OPAT. https://t.co/4YcFyjr76b
@JosephSassineMD @OURxResidency @EmilySiegrist4
cambridge.org
Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy - Volume 5 Issue 1
0
1
3
There is limited data on the need for monitoring with daptomycin in OPAT. Our OPAT team lead by Meaghan Wiley examined this question in 127 OPAT patients. They were on daptomycin (median 7.4 mg/kg) for a median of 37 days. 11.8% experienced CK elevation with a median of 13 days
1
2
3
Happy to start in a new role as Associate Chief Medical Officer for Cancer Services here at @OUHealth @StephensonCC. Looking forward to serving our patients here in Oklahoma and working alongside colleagues to provide cutting edge cancer therapies and clinical trials
18
9
110
Proud to see our Mandells PPID chapter on the antibiotic pipeline published. A huge career bucket list item for me since I started in ID. Special thanks to my collaborators: our editor @yohei_doi and co-authors @MattMil81732351 and Gerry Barber.
2
2
28
We are recruiting for a 4th inpatient ID pharmacist to join our team at Vanderbilt! We work with amazing providers, precept learners, and have a robust stewardship program. https://t.co/OvP9LeOOq9
0
4
10
It’s out! IDSA #cUTI guidelines 7/17/25. Now the fun begins….😌 #IDTwitter #TwitteRx @IDSAInfo
https://t.co/oOysnMCZYE
idsociety.org
1
16
62
ID fellowship applicants, make sure to check out our program @OUCollegeofMed: 2 year clinical program - 3 tracks (TxID, hosp epi, trop med) - Path for crit care fellowship - 12 credit certificates in year 2 https://t.co/qVUWU08zr2
3
5
19
Taxonomy shift 🚨 Candida auris has been reclassified as Candidozyma auris (C auris ) to reflect its distinct genetic profile from other Candida species. #IDXposts
5
43
134
🎉Please join us in welcoming Residency Class of 2026! Today marks the start of a new residency year, and we are thrilled to begin this journey with an exceptional group of residents. We are looking forward to a great year! #OUPharmacy #OUPharmacyResidency #PharmacyResidency
0
1
3
🎓 Congrats to our Residency Class of 2025! We’re so proud of all you’ve accomplished and can’t wait to see what’s next. 👏 A big shoutout to Dr. Corey Guidry, our 2024–25 Outstanding Preceptor of the Year! Thank you to all our amazing preceptors for your support! #OUPharmacy
0
2
2
Out now in @jac_amr, our real world analysis of BCID fungal panel for diagnosis of fungemia, led by the great @Emily_Siegrist - Sensitivity of 94%, lower than anticipated @bryan_p_white @RitaWilsonDib1 @OUCollegeofMed @OUHealth
https://t.co/y0KmnKJ3mG
academic.oup.com
Abstract. Bloodstream infections due to yeast are associated with a high mortality rate. There is a lack of data that evaluate the real-world sensitivity o
0
7
24
Super job by my @UGAPharmacy colleague @DBChastain leading this review (FREE Open Access): Adjunctive β-lactams for Staphylococcus aureus bacteremia: a narrative review
journals.sagepub.com
Staphylococcus aureus bacteremia (SAB) remains a major clinical challenge, with persistently high mortality despite advancements in antimicrobial therapy. The e...
1
6
20
Invasive fusariosis after CAR T is rare but can be consequential. Here’s our case of cutaneous fusariosis after CD19 CAR T, with @RitaWilsonDib1 @Emily_Siegrist @ouholter @joseandres2910 and others, out in @ASMicrobiology Case Reports! @OUCollegeofMed
https://t.co/ckW7hyN82x
journals.asm.org
Invasive fusariosis is a rare entity that primarily affects patients with hematological malignancies and recipients of hematopoietic cell transplants. Cases of mold infections in chimeric antigen...
2
10
30
Our real world study is the 1st (to our knowledge) to detail widespread restriction of remdesivir with patients that represent present-day epidemiology in the era of near universal SARS-CoV-2 seropositivity. In CID 📖 @BrentFooter @EB_Hirsch
#IDTwitter
https://t.co/cBtH4sHm0D
academic.oup.com
This pre-post quasi-experimental study evaluated the impact of a remdesivir restriction. Post-intervention, remdesivir was available for symptomatic immuno
2
15
38
Welcome our newest Pharmacy Residents — the Residency Class of 2026! A big congratulations as well to our current PGY1 Pharmacy residents for the next phase of their pharmacy development! #OUPharmacyResidency #ASHPMatch #PharmacyResidents
0
2
5